Common cold virus antibodies accidentally target liver cancer — revealing a surprising natural defense mechanism

Common cold virus antibodies accidentally target liver cancer — revealing a surprising natural defense mechanism

A remarkable and unexpected finding: antibodies that people make against common enteroviruses (like rhinoviruses that cause colds) may cross-react with liver cancer cells, providing a measure of natural immune protection against hepatocellular carcinoma (HCC).

Researchers found that antibodies targeting CE1, a consensus epitope shared among enteroviruses and rhinoviruses, are associated with reduced HCC incidence and mortality in patients. These anti-CE1 antibodies selectively bind to HCC cells and activate NK cells to kill them via antibody-dependent cellular cytotoxicity (ADCC). The mechanism: CE1 shares sequence similarity with ASPH (aspartate β-hydroxylase), a protein aberrantly overexpressed in HCC. So anti-viral antibodies, via molecular mimicry, end up recognizing a cancer antigen.

This is a striking example of host-microbe interaction benefiting cancer immune surveillance — and it could be exploited therapeutically by developing vaccines or antibodies targeting the CE1/ASPH epitope.

Key Findings

• Anti-CE1 antibodies (targeting enterovirus/rhinovirus epitope) are associated with reduced HCC incidence and mortality
• Anti-CE1 antibodies cross-react with ASPH, a protein overexpressed in hepatocellular carcinoma
• Cross-reaction occurs due to sequence homology between CE1 and ASPH
• NK cell-mediated ADCC is the mechanism by which anti-CE1 antibodies kill HCC cells
• ASPH expression in HCC correlates with the viral infection history signature

Implications

This finding could lead to cancer vaccines or therapeutic antibodies designed around the CE1/ASPH epitope. It also suggests that prior enteroviral infection history might influence HCC risk and could partly explain geographic and demographic variation in liver cancer incidence. A viral-epitope-based cancer immunotherapy approach would be novel and potentially broadly applicable.

Caveats

Preprint, not peer reviewed. Causality between anti-CE1 antibody titers and HCC protection needs prospective validation. The clinical significance of ADCC activity in human patients would need to be demonstrated in trials. Summary based on abstract only.

Source: bioRxiv — 2026-04-10